22nd Century Group (XXII) Projected to Release Earnings on Tuesday

22nd Century Group (NASDAQ:XXII) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect 22nd Century Group to announce earnings of ($3.00) per share and revenue of $8.42 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 7:00 AM ET.

22nd Century Group (NASDAQ:XXII) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($15.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($9.60). The business had revenue of $2.86 million for the quarter, compared to analyst estimates of $7.48 million. 22nd Century Group had a negative return on equity of 69.37% and a negative net margin of 27.04%.

22nd Century Group Stock Down 55.3%

Shares of NASDAQ:XXII opened at $0.09 on Tuesday. The company has a quick ratio of 1.90, a current ratio of 2.61 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $48.09. 22nd Century Group has a fifty-two week low of $0.09 and a fifty-two week high of $540.00. The company has a market cap of $45,614.40, a price-to-earnings ratio of -0.00 and a beta of 0.72.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 22nd Century Group in a research report on Monday. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About 22nd Century Group

22nd Century Group, Inc is a biotechnology and tobacco company focused on developing products with reduced nicotine content. Its technology is designed to alter the nicotine levels in tobacco plants, with the goal of supporting smoking cessation and reducing exposure to nicotine among adult smokers.

The company’s best-known products include VLN cigarettes, which contain substantially less nicotine than conventional cigarettes. VLN received authorization from the U.S. Food and Drug Administration to be marketed as a modified-risk tobacco product.